PT - JOURNAL ARTICLE AU - Wang, Jing AU - Yang, Ying AU - Xu, Luxinyi AU - Shen, Yuan AU - Wen, Xiaotong AU - Mao, Lining AU - Wang, Quan AU - Cui, Dan AU - Mao, Zongfu TI - The impact of National Centralized Drug Procurement policy on the use of policy-related original and generic drugs in public medical institutions in China: A difference-in-difference analysis based on national database AID - 10.1101/2021.06.21.21256568 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.21.21256568 4099 - http://medrxiv.org/content/early/2021/06/28/2021.06.21.21256568.short 4100 - http://medrxiv.org/content/early/2021/06/28/2021.06.21.21256568.full AB - Objective To evaluate the impact of the first round of the National Centralized Drug Procurement (NCDP) pilot (referred to as “4+7” policy) on the use of policy-related original and generic drugs.Methods Drug purchase data from the China Drug Supply Information Platform (CDSIP) database were used, involving nine “4+7” pilot cities and 12 non-pilot provinces in China. “4+7” policy-related drugs were included, which consisted of 25 “4+7” List drugs and 97 alternative drugs that have an alternative relationship with “4+7” List drugs in clinical use. “4+7” List drugs were divided into bid-winning and non-winning products according to the bidding results. Purchase volume, purchase expenditures, daily costs were selected as outcome variables, and were measured using Defined Daily Doses (DDDs), Chinese Yuan (CNY), and Defined Daily Drug cost (DDDc), respectively. Difference-in-Difference (DID) method was employed to estimate the net effect of policy impact.Results After policy intervention, the DDDs of original drugs among “4+7” List drugs significantly reduced by 124.59%, while generic drugs increased by 52.12% (all p-values <0.01). 17.08% of the original drugs in DDDs were substituted by generic drugs. Prominent reductions of 121.69% and 80.54% were observed in the expenditure of original and generic drugs, with a total cost-saving of 5036.78 million CNY for “4+7” List drugs. The DDDc of bid-winning original and generic drugs, as well as non-winning original drugs, significantly decreased by 33.20%, 75.74%, and 5.35% (all p-values <0.01), while the DDDc of non-winning generic drugs significantly increased by 73.66% (p<0.001). The use proportion of bid-winning products and non-winning original drugs raised prominently from 39.66% to 91.93%Conclusions “4+7” policy promoted the substitution use of generic drugs against original drugs, which conducive to drug costs saving. The overall quality level of drug use of public medical institutions significantly increased after “4+7” policy, especially in primary medical institutions.Strengths and limitations of this study➢ The “4+7” policy is the first policy attempt of volume-based drug procurement work at the national level in China, and is a pioneering work in the reform of Drug Supply and Guarantee System in China. This study aimed to explored the effect of this policy on original and generic drug use in China.➢ This study used data of national database – China Drug Supply Information Platform (CDSIP). The monthly drug purchase data of nine pilot cities and twelve non-pilot provinces in mainland China were analyzed.➢ This study used Difference-in-Difference analysis to evaluate the policy effect.➢ The findings based on drug purchase data rather than drug use data in the present study might limit the interpretation and extrapolation of research results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Global Health Institute, Wuhan University, China. The role of funding body included designing the study, analysis and interpretation of data, and writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was reviewed and approved by the Institutional Review Board of Faculty of Medical Sciences, Wuhan University (IRB number: 2019YF2050). In this study, we only included the drug procurement information and all the information was anonymous. Neither patients nor the public were involved in this research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study is not publicly available. The dataset (CDSIP database) used and analyzed during the current study is available from the corresponding author on reasonable request. In this study, no additional data is used.